Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-KLK2/CD3 bispecific antibody JNJ-78278343

A T-cell-redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T cells, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, anti-KLK2/CD3 bispecific antibody JNJ-78278343 binds to both CD3 on T cells and KLK2 on KLK2-expressing tumor cells. The resulting cross-linkage activates and redirects T cells to KLK2-expressing tumor cells. This results in T-cell-mediated lysis of KLK2-expressing tumor cells. KLK2 is overexpressed in certain tumors, including prostate adenocarcinoma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:T-cell redirecting agent JNJ-78278343
Code name:JNJ 78278343
JNJ-78278343
JNJ78278343
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search